Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome

What users commonly report: Continued gradual fat loss, but slower than weeks 6-8 Body composition improvements consolidate Some users plateau around week 10 Decision point: Most protocols recommend stopping at 8-12 weeks with a 4-6 week break before repeating
The most common side effects associated with facial fillers occur at the injection site and include minor redness, bruising, discomfort, or swelling
Yes, our BPC-157 products are also formulated without gluten, dairy, and soy